Skip to content
Open·Synced from source July 16, 2026

NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)

National Institutes of Health

Apply at National Institutes of Health

Free. Verify your email, then we send one reminder only.

Posted
Dec 17, 2025
Closes
Jan 7, 2027 (in 175 days)
Last verified
Jul 16, 2026

Classification and identifiers

Solicitation number
PAR-25-032
Assistance listing (CFDA)
93.838

Amount

Amount not published by the funder

Who can apply

School districtsLocal governmentsFor-profitsSmall businessCounty governmentsTribal organizations

Local government agencies and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defi...

About this opportunity

This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, a...

Refine this search